vs
Ascendis Pharma A/S（ASND）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
Ascendis Pharma A/S的季度营收约是MARCUS CORP的1.4倍（$267.3M vs $193.5M），Ascendis Pharma A/S同比增速更快（42.3% vs 2.8%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs 18.2%）
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
ASND vs MCS — 直观对比
营收规模更大
ASND
是对方的1.4倍
$193.5M
营收增速更快
ASND
高出39.6%
2.8%
两年增速更快
ASND
近两年复合增速
18.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $193.5M |
| 净利润 | — | — |
| 毛利率 | 90.5% | — |
| 营业利润率 | — | 0.9% |
| 净利率 | — | — |
| 营收同比 | 42.3% | 2.8% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASNDMCS
| Q4 25 | $267.3M | $193.5M | ||
| Q3 25 | $230.7M | $210.2M | ||
| Q2 25 | $170.7M | $206.0M | ||
| Q1 25 | $109.0M | $148.8M | ||
| Q4 24 | $187.8M | $188.3M | ||
| Q3 24 | $62.5M | $232.7M | ||
| Q2 24 | $38.9M | $176.0M | ||
| Q1 24 | $103.6M | $138.5M |
净利润ASNDMCS
| Q4 25 | — | — | ||
| Q3 25 | $-65.9M | $16.2M | ||
| Q2 25 | $-42.0M | $7.3M | ||
| Q1 25 | $-102.2M | $-16.8M | ||
| Q4 24 | — | $986.0K | ||
| Q3 24 | $-107.1M | $23.3M | ||
| Q2 24 | $-118.1M | $-20.2M | ||
| Q1 24 | $-141.5M | $-11.9M |
毛利率ASNDMCS
| Q4 25 | 90.5% | — | ||
| Q3 25 | 89.5% | — | ||
| Q2 25 | 80.1% | — | ||
| Q1 25 | 82.6% | — | ||
| Q4 24 | 91.9% | — | ||
| Q3 24 | 80.6% | — | ||
| Q2 24 | 68.2% | — | ||
| Q1 24 | 92.1% | — |
营业利润率ASNDMCS
| Q4 25 | — | 0.9% | ||
| Q3 25 | 5.1% | 10.8% | ||
| Q2 25 | -33.5% | 6.3% | ||
| Q1 25 | -103.2% | -13.7% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | -167.3% | 14.1% | ||
| Q2 24 | -370.2% | 1.3% | ||
| Q1 24 | -51.2% | -12.0% |
净利率ASNDMCS
| Q4 25 | — | — | ||
| Q3 25 | -28.5% | 7.7% | ||
| Q2 25 | -24.6% | 3.6% | ||
| Q1 25 | -93.7% | -11.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | -171.5% | 10.0% | ||
| Q2 24 | -303.9% | -11.5% | ||
| Q1 24 | -136.6% | -8.6% |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.3M | $23.4M |
| 总债务越低越好 | — | $159.0M |
| 股东权益账面价值 | $-175.8M | $457.4M |
| 总资产 | $1.4B | $1.0B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资ASNDMCS
| Q4 25 | $665.3M | $23.4M | ||
| Q3 25 | $582.2M | $7.4M | ||
| Q2 25 | $533.6M | $14.9M | ||
| Q1 25 | $559.4M | $11.9M | ||
| Q4 24 | $604.3M | $40.8M | ||
| Q3 24 | $675.6M | $28.4M | ||
| Q2 24 | $279.4M | $32.8M | ||
| Q1 24 | $345.9M | $17.3M |
总债务ASNDMCS
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | — | $173.1M | ||
| Q2 24 | — | $175.7M | ||
| Q1 24 | — | $169.8M |
股东权益ASNDMCS
| Q4 25 | $-175.8M | $457.4M | ||
| Q3 25 | $-188.0M | $454.3M | ||
| Q2 25 | $-202.6M | $448.4M | ||
| Q1 25 | $-205.0M | $441.8M | ||
| Q4 24 | $-114.2M | $464.9M | ||
| Q3 24 | $-105.1M | $462.3M | ||
| Q2 24 | $-346.8M | $449.4M | ||
| Q1 24 | $-257.2M | $459.3M |
总资产ASNDMCS
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.2B | $1.0B | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.2B | $1.0B | ||
| Q2 24 | $819.0M | $1.1B | ||
| Q1 24 | $866.7M | $1.0B |
负债/权益比ASNDMCS
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.2M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | — | $26.4M |
| 自由现金流率自由现金流/营收 | — | 13.6% |
| 资本支出强度资本支出/营收 | — | 11.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $989.0K |
8季度趋势，按日历期对齐
经营现金流ASNDMCS
| Q4 25 | $58.2M | $48.8M | ||
| Q3 25 | — | $39.1M | ||
| Q2 25 | — | $31.6M | ||
| Q1 25 | $-15.5M | $-35.3M | ||
| Q4 24 | $-330.7M | $52.6M | ||
| Q3 24 | — | $30.5M | ||
| Q2 24 | — | $36.0M | ||
| Q1 24 | $-109.7M | $-15.1M |
自由现金流ASNDMCS
| Q4 25 | — | $26.4M | ||
| Q3 25 | — | $18.2M | ||
| Q2 25 | — | $14.7M | ||
| Q1 25 | — | $-58.3M | ||
| Q4 24 | — | $27.1M | ||
| Q3 24 | — | $12.0M | ||
| Q2 24 | — | $16.1M | ||
| Q1 24 | — | $-30.5M |
自由现金流率ASNDMCS
| Q4 25 | — | 13.6% | ||
| Q3 25 | — | 8.7% | ||
| Q2 25 | — | 7.1% | ||
| Q1 25 | — | -39.2% | ||
| Q4 24 | — | 14.4% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 9.2% | ||
| Q1 24 | — | -22.0% |
资本支出强度ASNDMCS
| Q4 25 | — | 11.6% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | — | 13.5% | ||
| Q3 24 | — | 7.9% | ||
| Q2 24 | — | 11.3% | ||
| Q1 24 | — | 11.1% |
现金转化率ASNDMCS
| Q4 25 | — | — | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 4.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASND
暂无分部数据
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
